Fort Washington Investment Advisors Inc. OH Has $34.43 Million Holdings in Haemonetics Corporation $HAE

Fort Washington Investment Advisors Inc. OH grew its position in Haemonetics Corporation (NYSE:HAE) by 36.2% in the third quarter, according to its most recent filing with the SEC. The fund owned 706,312 shares of the medical instruments supplier’s stock after acquiring an additional 187,630 shares during the period. Fort Washington Investment Advisors Inc. OH’s holdings in Haemonetics were worth $34,426,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Quarry LP increased its holdings in Haemonetics by 63.4% in the 1st quarter. Quarry LP now owns 495 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 192 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in shares of Haemonetics by 2,640.0% in the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after buying an additional 396 shares during the period. GAMMA Investing LLC increased its stake in shares of Haemonetics by 59.4% in the second quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier’s stock valued at $33,000 after buying an additional 165 shares during the period. UMB Bank n.a. raised its holdings in Haemonetics by 91.7% in the 2nd quarter. UMB Bank n.a. now owns 669 shares of the medical instruments supplier’s stock valued at $50,000 after buying an additional 320 shares during the last quarter. Finally, Elevation Point Wealth Partners LLC acquired a new stake in Haemonetics during the 2nd quarter worth approximately $64,000. Institutional investors own 99.67% of the company’s stock.

Haemonetics Stock Up 0.3%

Shares of NYSE:HAE opened at $80.54 on Tuesday. Haemonetics Corporation has a 1 year low of $47.31 and a 1 year high of $87.32. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.64 and a quick ratio of 1.03. The business’s 50-day moving average is $72.07 and its 200-day moving average is $65.19. The company has a market capitalization of $3.77 billion, a price-to-earnings ratio of 23.55, a P/E/G ratio of 1.51 and a beta of 0.29.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share for the quarter, topping analysts’ consensus estimates of $1.12 by $0.15. The business had revenue of $327.32 million during the quarter, compared to the consensus estimate of $311.61 million. Haemonetics had a return on equity of 27.22% and a net margin of 12.67%.The firm’s revenue for the quarter was down 5.3% on a year-over-year basis. During the same period in the previous year, the company posted $1.12 earnings per share. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. Equities research analysts predict that Haemonetics Corporation will post 4.55 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on HAE shares. Needham & Company LLC downgraded shares of Haemonetics from a “buy” rating to a “hold” rating in a research note on Monday, December 15th. Mizuho increased their price objective on Haemonetics from $75.00 to $90.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Raymond James Financial reaffirmed an “outperform” rating and set a $90.00 target price on shares of Haemonetics in a research report on Friday, November 14th. CJS Securities upgraded Haemonetics to a “strong-buy” rating in a research report on Thursday, December 11th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Haemonetics in a research report on Monday, December 22nd. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $84.10.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.